Indication
Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma
1 clinical trial
1 product
Product
ATA3219Clinical trial
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2026-05-01